$0.30
$6.90
bear $0.30
base $1.05
bull $6.90
margin of safety $0.65
market price* $2.17
Perspective Therapeutics develops cancer drugs that attach the radioactive element lead-212 to molecules that seek out tumor cells, so that the radiation is delivered directly to the cancer. It has no approved product and no product sales. Its only revenue is small research grant income. Before 2023 the company was Isoray, a small seller of radioactive seeds for prostate cancer; that business was discontinued after the January 2023 merger with Viewpoint Molecular Therapeutics, and the earlier years describe a different company. Three drugs are in early first-in-human (Phase 1/2a) trials: VMT-alpha-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors that express fibroblast activation protein. The most advanced, VMT-alpha-NET, had treated 56 patients as of December 2025 with no dose-limiting toxicities, no treatment-related discontinuations and no serious kidney problems; about 38% had a grade 3 or worse adverse event, one a transient grade 4 drop in lymphocyte count. Efficacy in these small early studies is not proof of an approvable drug. There are no earnings to value, so this is an estimate of what the business holds and what it is likely to do with it. Cash used by the business, after capital spending and the cost of stock given to employees, was about $3.5 million in the year to June 2021, $44.6 million in 2023, $109.9 million in 2024 and $105.9 million in 2025, and ran at roughly $79 million in the first half of 2026 alone. We adjusted the 2024 figure for a $28 million up-front payment from a Lantheus affiliate for an option to negotiate a license to VMT-alpha-NET; that cash arrived in 2024 but is booked as deferred income and is non-refundable, so it is a one-time receipt, not a recurring earning, and it is not a debt. We left in the add-back of non-cash write-offs (a $24 million goodwill write-down in 2024 and a $10 million write-down of acquired research in 2025) because they are sunk costs, not ongoing spending. At June 30, 2026 the company held $236.9 million of cash and short-term investments after a $175 million stock sale in February 2026, and owed only about $1.7 million of notes. Spending is rising as it prepares for larger trials, and the company itself says its cash funds current plans into late 2027, so more stock will almost certainly be sold. There are about 120.7 million diluted shares (including pre-funded warrants). Property and equipment is $107.8 million on the books, but most of it is production suites, equipment and improvements built in leased space (the Somerset, New Jersey plant was bought from Lantheus for only $8 million and sits in a leased building), so little of it would come back if the programs stopped. Bear case, about $0.30 per share. Early data disappoint in the coming year, the company keeps spending about $168 million over twelve months and a further quarter at a reduced rate while it decides, then shuts the programs. About $37 million of cash is left after $1.7 million of debt, shutdown costs of about $15 million (severance, trial close-outs, leases) are paid, and roughly 10% of the plant and equipment book value, about $15 million, is recovered. The business is worth about $52 million, it owes about $15 million to wind down, and the difference is about $37 million, or roughly $0.30 a share. The industry's own record supports this case: most cancer drugs entering human trials never reach approval. Base case, about $1.05 per share. The programs keep producing clean safety data and continue into 2027, the company spends about $168 million in the next twelve months and has about $67 million of cash after debt by mid-2027. We credit the plants and equipment at about 25% of their book value (about $37 million) because they are specialized, working production assets, and we credit the drug platform at $28 million, the amount Lantheus actually paid for its option. We give no value to approval or sales of any drug because none is secured by a contract, pivotal result or approval. The total is about $132 million, worth about $127 million today, or $1.05 a share, with no debt of consequence. The base is below today's cash per share because the money being spent has no value we can evidence until results arrive. Bull case, about $6.90 per share. VMT-alpha-NET confirms its early promise, the existing Lantheus option or a similar acquirer leads to a takeout, as happened to comparable companies (BMS bought RayzeBio, Lilly bought POINT Biopharma and AstraZeneca bought Fusion Pharmaceuticals), and the company raises about $250 million more at around $5 to reach it. At a $1.3 billion price and about 171 million shares, that is $7.60 in 2028, or about $6.90 today. Debt is immaterial in this case. What changed since our September 2026 estimate: cash per share is about the same after the February offering, early safety data for VMT-alpha-NET have kept building, and the quarterly burn has risen to about $73 million of cash in the first half of 2026. We also found that the manufacturing sites are mostly leased space, which lowers what the plants would fetch. We previously gave weight to the chance of drug success; this estimate gives no value to success that has not yet been secured, so the older $0.40, $2.60 and $11.00 are not comparable. What would make this wrong: efficacy data in a registrational-size study that clearly beat existing options would make the bull case much more likely; a serious safety event, a clinical hold or a financing at a very low price would push toward the bear case. Radioactive drug supply is also demanding, since lead-212 decays quickly, so manufacturing delays are a real risk. The margin-of-safety price is $0.65. We are uncertain about the burn rate and about what the plants would fetch, and the worst plausible outcomes (a safety setback, a forced low-priced financing, a plant shutdown with leftover lease costs) could leave shareholders with a small fraction of today's cash. That price covers roughly the cash left after another year of spending plus a small part of the plants, and assigns no value to the drug platform or any pipeline success. The shares pay no dividend, so any return depends wholly on results reaching the share price, and the price assumes a holding period through 2027 for the main data and financing.